INFO_02b j.qxd - Bosnalijek dd

Summary
Pages 4 and 5
Interview
Zoltan Csizer,
UNIDO Director of Cleaner
Production and Enviromental
Managment Branch
New tablets plant - a modern
world class quality
pharmaceutical plant
Additional funds for this type of project
have, as you know, been provided
thanks to extremley high engagment
of the company’s top managment.
You are following its implementation.
Are you satisfied?
You have proably seen the Injectables
Plant too. We shall appreciate to hear
your assessment for both?
I have seen the Injectables Plants
when it was in less advanced construc-
Page 6
A heavy task
R & D is successfully
reaching
the strategic goal
of bosnalijek
In recent years, through introduction
of the whole range of
new drugs in production,
Bosnalijek is realizing its strategic
goal: expand its products
range and meeting about 60% of
B-H populations demands, thus
Page 9
Partnership * foreign contacts
Eli Lilly
Middle of Marchthis year Bosnalijek
has concluded two extraordinary significant
business arrangements with
American company Eli Lilly, the following
statements were released:
Edin Arslanagi}, General Manager
of Bosnalijek:
- I must express my satisfaction that
after 8 month of negotiations, we
managed to execute this agreement
tion stage than the Tablets Plant is
Today. I am telling this based on a
very short visit where I was polite
enough not to put many questions. I
would say that it is extremley difficult
to create something new wich meets
the international standards in an
building structure.
The other facility, the Tablets
Production Plant is different. First,
that was a larger building and as we
saw from the video it was scaled
dowwn up to the skeleton of the
building and everything is quite
brand new now. That almost a green
field new construction. And of course,
what I have seen I like very much.
That will be a modern, world class
quality, new pharmaceutical plant.
How do you see Bosnalijek tomorrow,
do you hav some suggestion in that
respect?
I don’t want to encourage or discourage
anybody, but the future of
Bosnalijek is not going to be easy. I
personally belive that the very capable
making Bosnalijek the leading
drug supplier of this market.
Great contribution here was
given by R & D Division which,
in accordance with very strict
international standards of development,
its testing and introducing
drugs in production in form
of tablets, capsules,syrups, suspensions,
ointaments, creams,
jellies, injections solutions, etc.
Implementation of a new drug
development is running in specilized
laboratories:
which will result in our better bids.
It will be just that what this market
was missing. I am particulary pointing
out to human insulins.
Our goal is, as known, to make
Bosnalijek leader in supplying
Bosna-Hercegovina market with
drugs. In this way the goal will be
easier of attainment. The agreement
is made for 5 years period and will
encompass 33 new drugs of very
good quality, thus expanding our
product range by 20%. I think that
it is only the first phase of our
cooperation. In fact, I am expecting
Bosnalijek and Eli Lilly to find out
managment of Bosnalijek knows that
well. But what I have seen in the last
couple of years, and I became almost
friend to many of the high managers
of the company, that after long they
bring very wise and smart decision.
One of the most important decisions
was not to move back for chemical
synthesis. And we should face the fact
that for time being Bosnalijek is
small company and realistic target of
a small company can be and shall be
only to make that part of production
which has the highest profit. As for
the future decisions, I would like to
advise you that as long as the country
has get the priorites through the law
you should go for some modern
generics formulations wich are just
out from the patent protection. With
this approach you will have success
and make a very important to get
some sort of cooperation with some
other companies in the outside world.
And up to now Bosnalijek has already
made this type of effort, among other
- pharmaceutical technology laoratories
- analytic laboratory
- stability tests laoratory
Contiuous training aboard
(attending symposia, congresses,
courses) exchange of professional
information and experience with
foreign partners (Lilly, novartis,
Biochemie, API, IMP
Fisiopharma, PHARCO,...). for
the purpose of improvment of
quality and introduction of new
knowledge for the future programs,
as well as advanced train-
some other ways of their mutual
performance in even better quality.
Eberhard Ludewigs, General manager
of Eli Lilly in charge of Hungary,
Slovenia, Croatia an Bosnia-
Hercegovina:
- In countries in which we ha not
een present so far we are searching
for the best partners. Our products
range covers five therapeutic areas:
endocrinology, mainly with insulin
products, then we have wide range of
antibiotics for oral administration
and in form of ampoules, products
countries specifically with Slovenia. I
know that a part of technological
know-how for this new project is
coming from LEK.
And the last point whichI would like
to emphasize and I know that the
company did enough in this issue, is
that the local market is so small that
it would be so difficult to belive in
the long run this company can function
with such a small local market. i
have heard that Bosnalijek is trying to
make export to Ukraina, in fact there
is interest there. Considering the
political situation, I presume that
Ukraina would not be too happy if
they would need to buy all their
drugs from Russia. That gives a good
opportunity for the company. They
will certanly be numerous. That
should be dealt with, and you in
Bosnalijek know how to proceed.
Interviewers:
A. Kapi} and
B. Avdiegovi}
ing through post-graduate studies
and specialist training, is
guaranty for realization of strategic
goas of the company.
This supported by the Expert
Committee (composed of different
profile experts), as well as
Scientific Council composed of
prominent professors in areas of
medecine, pharmacy, chemistry.
Midhat Vehabovi},
B. S. Pharm. Spec.
for cardiovascular diseases, anticancer
products as well as products
for treatment of central nervous system
diseases.
These are treatment areas in the
world in wich Eli Lillyhas advantage
over other companies. All these
areas, all these drugs, are covered by
this agreement.
Along with these activities, as said
Mr. Arslanagi}, we shall be making
plans for our mutual approach to
the market. These activities will be
coordinated in the best possible way.